Steve Bloor is the CEO of Videregen, a clinical-stage regenerative medicine company to develop personalised, non-immunogenic organ and tissue replacement products for chronic and orphan indications. He has more than 25 years of experience in the medical device and regenerative medicine industry. He has worked in US multinationals (J&J, Covidien) and UK start-up companies, with specific expertise in leadership roles. strategic R&D, clinical compliance and regulation.

Steve was formerly CSO at Tissue Science Laboratories and was behind the development of TSL’s tissue replacement technology. He subsequently became VP of  R&D at Covidien following their $80m acquisition of TSL in 2008.